| Literature DB >> 31516319 |
Adil Farooq Wali1, Sabhiya Majid2, Shabhat Rasool2, Samar Bassam Shehada1, Shahad Khalid Abdulkareem1, Aimen Firdous3, Saba Beigh4, Sheeba Shakeel5, Saima Mushtaq6, Imra Akbar7, Hassan Madhkali8, Muneeb U Rehman2.
Abstract
Marine natural products have as of now been acknowledged as the most important source of bioactive substances and drug leads. Marine flora and fauna, such as algae, bacteria, sponges, fungi, seaweeds, corals, diatoms, ascidian etc. are important resources from oceans, accounting for more than 90% of the total oceanic biomass. They are taxonomically different with huge productive and are pharmacologically active novel chemical signatures and bid a tremendous opportunity for discovery of new anti-cancer molecules. The water bodies a rich source of potent molecules which improve existence suitability and serve as chemical shield against microbes and little or huge creatures. These molecules have exhibited a range of biological properties antioxidant, antibacterial, antitumour etc. In spite of huge resources enriched with exciting chemicals, the marine floras and faunas are largely unexplored for their anticancer properties. In recent past, numerous marine anticancer compounds have been isolated, characterized, identified and are under trials for human use. In this write up we have tried to compile about marine-derived compounds anticancer biological activities of diverse flora and fauna and their underlying mechanisms and the generous raise in these compounds examined for malignant growth treatment in the course of the most recent quite a long while.Entities:
Keywords: Anti-cancer; Corals; Marine; Marine herbs; Natural products; Seaweeds
Year: 2019 PMID: 31516319 PMCID: PMC6733955 DOI: 10.1016/j.jsps.2019.04.013
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
Fig. 1Different marine resources having anti-cancer potential.
Fig. 2Structures of some of the marine natural products from various sources.
Listed of compounds approved/clinical trials phase isolated marine sources.
| Clinical Status | Compound Name | Refs. |
|---|---|---|
| FDA-EMA Approved | Cytarabine, ARA-C | |
| Trabectedin | ||
| Brentuximab vedotin | ||
| Phase III | Plitidepsin | |
| Neovastat® | ||
| Pseudopterosins | ||
| Phase I/II | Gemcitabine | |
| Elisidepsin | ||
| Kahalalide-F | ||
| PM1004 | ||
| Phase I | Hemiasterlin | |
| Taltobulin | ||
| Spisulosine | ||
| Bryostatin 1 | ||
Listed of moleclues isolated from various marine sources.
| Source | Compounds isolated | Refs. |
|---|---|---|
| Marine Algae | Nitrogen-containing heterocyclics, kainic acids, guanidine derivatives, phenazine derivatives, amines, sterols | |
| Sulfated polysaccharides | ||
| Prostaglandins | ||
| Corals Reefs | Cytosar-U® | |
| Dolastatin | ||
| Nitrogenous diterpene | Cooper et al., 2011; | |
| Non-cembranoidal diterpene 5-episinuleptolide acetate | ||
| Sterols | ||
| Cembranolides like lobomichaolide and michaolides | ||
| Marine Herbs | Bryostain, Sorbicillactone A and Sorbicillactone B | |
| Borophycin | ||
| (2R,3R)-3′,4′,5,5′,7-pentahydroxyflavan-3-yl gallate, and 3,4,5-Trihydroxybenzoic acid | ||
| Fucoidan | ||
| Lophocladine A & B | ||
| Halomon-A penta halogenated monoterpne | ||
| Stigmast | ||
| Marine Sponges | A tetrahydroiso-quinoline | |
| Spongistatin-I | ||
| Heteronemin | ||
| Manzamine A, | ||
| Marine Fungi | A pimarane-type diterpenes, Scopararane I | |
| Varioloid A | ||
| Simplicilliumtides A-H | ||
| Azaphilonidal, penicilazaphilones B and C | ||
| Secalonic acid D | ||
| Sea Weeds | Dexcyanidanol, catechuic acid and trihydroxybenzoic acid | |
| Marine Bacteria | Quinine derivatives analogues like driamycin, daunorubicin, mitomycin C, streptonigrin, and lapachol, | |
| Marine Ascidiaceans | Eudistomins, eilatin, staurosporine derivatives, methyleudistomins and pibocin | |
| Halocynthiaxanthin and fucoxanthinol | ||
| Meridianins, brominated 3-(2-aminopyrimidine)-indoles | ||
| Marine diatoms | 2- | |